Corbus Pharmaceuticals Announces Updated Data From CRB-701 Study, Stock Down In Pre-Market
Corbus Pharmaceuticals (CRBP) reported updated Phase 1/2 data for CRB-701 in 2L oropharyngeal and cervical cancers, based on an April 1, 2026 cut with 317 patients. It cited ORR of 42.9% (median DOR 6.3 months, PFS 5.6) in OPSCC and 34.4% (DOR 8.0, PFS 4.3) in cervical cancer. The company plans registrational trials starting with TEMPO-1 in summer 2026; shares were down 12.79% pre-market to $9.90.
How this was made
The 30-second read
Why it matters
The update confirms ORR/PFS and supports the company’s strategy beyond metastatic urothelial cancer, but the market sold the news, implying expectations or interpretation of the dataset were unfavorable.
Market read
Clinical efficacy/durability readout plus a registrational-trial roadmap is a direct catalyst for CRBP, and the pre-market drop signals investors are reassessing near-term probability/valuation.
What to watch
Key details like prior dataset comparisons, response depth across doses, safety/tolerability by subgroup, and how TEMPO-1 design/eligibility maps to the strongest signals are not provided here but likely drive the magnitude of the reaction.
Background
Corbus is running a Phase 1/2 CRB-701 study in 2L oropharyngeal and cervical cancers and is planning registrational trials starting with TEMPO-1 in summer 2026.
Ticker impact
Corbus reported updated Phase 1/2 CRB-701 efficacy/safety data and said it validates its solid-tumor strategy, while the stock fell ~13% pre-market.
Bearish-to-volatile near term: despite favorable ORR/DOR/PFS, the market reaction suggests expectations were higher or prior read-through was more favorable.
The article provides specific clinical outcomes and an explicit pre-market selloff, indicating the market discounted the update or focused on dose/endpoint nuances and timing to registrational trials.
Market effects
Reinforces sentiment around solid-tumor ADC/targeted oncology development pathways and the importance of ORR/PFS durability in early-phase readouts.
Primarily US small/mid-cap biotech sentiment; could influence peer tape via risk appetite for oncology clinical updates.
Limited direct global catalyst beyond oncology trial read-through; mainly affects investors tracking US-listed biotech development timelines.
Counterpoint
The reported ORR and durability (median DOR ~6–8 months) could be sufficient for continued registrational progression; the selloff may reflect valuation/expectations rather than fundamental deterioration.
Key entities
- drug_candidateCRB-701
Corbus’ investigational therapy whose updated Phase 1/2 results were released for 2L oropharyngeal and cervical cancers.
- clinical_programTEMPO-1
Upcoming OPSCC study planned to start in summer 2026 as the first registrational trial step.
